BPC-157 Price: $24.50 a Vial, $2.45 a Milligram

Both listings carry the same 50% code, so the discounted column is the one to compare. What differs is what the milligrams are made of.

Read the last column before the second to last one. If BPC-157 is the only thing you want, the 10 mg vial at $24.50 is the cheaper route to it, and the $2.25 on the stack is an average across a blend. If you want both compounds, the stack is $45.00 for 20 mg of material instead of two separate orders.

Searches for bpc 157 price without the hyphen return the same two listings. There is no third size and no bulk-powder option to compare against, which makes this one of the simpler price pages to write and one of the easier ones to get wrong.

A price page usually stops at the vial. The vial is not the scale anyone measures in, so here is the same $24.50 read five ways.

Every row is the same transaction. $24.50 divided by 10 mg is $2.45 per milligram, and a 10 mg vial holds 10,000 mcg, so it contains one hundred 100 mcg portions at $0.245 each.

The last row cannot be written down until somebody states a volume. Reconstituted with 2 mL of bacteriostatic water the vial is 5 mg/mL, which is 200 units on a U-100 barrel, and $24.50 divided by 200 is $0.1225 a unit. Ten units on that barrel draws 500 mcg. Fill the same vial with 1 mL instead and it is 10 mg/mL, 100 units, and ten units draws 1 mg. The price did not move, the denominator did. Our syringe measurement guide covers reading the barrel and the reconstitution calculator will run any volume you enter.

The Wolverine Stack is one vial holding 10 mg of BPC-157 and 10 mg of TB-500, a synthetic fragment of thymosin beta-4. Twenty milligrams of peptide for $45.00 is $2.25 per milligram, and that is arithmetically correct. It is also the wrong comparison for anyone pricing BPC-157 on its own.

Split it the other way. If you bought the stack for the BPC-157 in it and counted the TB-500 as incidental, you paid $45.00 for 10 mg of BPC-157, which is $4.50 per milligram with a second compound alongside at no extra charge. The honest rate sits between $2.25 and $4.50 and depends on how much the TB-500 is worth to you, which is not a question a price page can answer.

Two separate vials are $49.00 for 20 mg of BPC-157. The stack is $45.00 for 10 mg of BPC-157 and 10 mg of something else. Those are different purchases at similar money, and the only way to choose badly is to set $2.45 against $2.25 as though the same substance sat behind both.

The published tiers take 3% off at three vials, 5% at five and 10% at ten, calculated from the $49.00 list price rather than from the discounted one.

The best rung on that ladder is $4.41 per milligram and reaching it costs $441.00. One vial with the code is $2.45 per milligram for $24.50, which is $1.96 a milligram cheaper. A 10% discount cannot catch a 50% one. Whether a checkout will apply a tier and the code together is a cart rule rather than a published one, so budget on the assumption that it does not, and read the coupon page for the checks that settle it.

Free carriage starts at $250, and where that line falls depends on which subtotal the cart measures. At $24.50 a vial, ten vials come to $245.00 and miss it while eleven come to $269.50 and clear it. At the $49.00 list price, five vials come to the same $245.00 and six come to $294.00. Freight also bites hardest on small orders: a flat $10.00 charge on one discounted vial is $1.00 per milligram, turning $2.45 into $3.45, an increase of 41%.

The search assumes a covered product with a cash fallback. BPC-157 has neither, and the reason sits well upstream of plan design.

Coverage runs through an approved product: a marketing authorisation, a national drug code, a labelled indication, a formulary line. BPC-157 holds none of those in the United States, the European Union or the United Kingdom, and never has. The FDA approved drug database returns no entry for it.

The compounding route is where most pages go stale, so it is worth the dates. BPC-157 was placed in FDA's Category 2 for nominated bulk substances in September 2023, and almost every page on the internet still stops there. In April 2026 FDA removed it from Category 2 after the nominations were withdrawn, which is a removal for further evaluation rather than a promotion to Category 1. At its meeting of 23 and 24 July 2026 the Pharmacy Compounding Advisory Committee narrowly recommended BPC-157 for the 503A Bulks List. That recommendation is non-binding, BPC-157 does not appear in 21 CFR 216.23, and FDA has made no final determination. Unapproved, out of Category 2, recommended but not listed. No compounded product means no compounded price. Our page on the prescription question takes the timeline apart properly.

There is also no dispensing event to bill. Research material is sold as a laboratory reagent against an order, not dispensed against a prescription, so there is no claim for a pharmacy to submit even if a plan wanted to pay one. Every BPC-157 cost quoted anywhere is a cash price on a research listing.

Per-milligram rates across research peptides span more than an order of magnitude, and the drivers are mundane: chain length, how awkward the synthesis and purification are, and how many people want the compound. BPC-157 is 15 residues, formula C62H98N16O22, around 1,419.5 g/mol. That is a short and well-established synthesis, which is part of why the rate is low. On this site MOTS-c works out at $3.75 per mg with the same code and the retatrutide listings at $4.95 and $4.17 per mg. BPC-157 sits below all three.

A lower price per milligram is a lower price, not a better deal. The tendon, ligament and gut findings behind BPC-157 are almost entirely rat and cell work, much of it from a single research group in Zagreb, and no human efficacy trial has reported. The first controlled test is only now under way: NCT07437547, a Phase 2 study of BPC-157 in acute hamstring strain sponsored by Hudson Biotech, 120 participants, started on 2 February 2026 with primary completion not before 14 February 2027. Retatrutide has a completed Phase 3 programme sitting behind its higher rate. Those are not the same purchase at two prices.

Two things the label price leaves out. Lyophilised peptide is weighed as a salt, so part of the mass in the vial is counterion and residual solvent rather than peptide, and how much is a question for the certificate covering your batch. Ascension publishes two third-party assays per batch, from Kovera Labs (batch #12-05260628) and MZ Biolabs (batch #12-01260229), and the batch on the certificate has to match the batch on the vial. Separately, a little solution stays in the vial shoulder and needle hub after the last draw, which is a loss against the mass you paid for rather than against the price.

Comparing suppliers rather than compounds runs in a fixed order: confirm the certificate covers the batch you will receive, convert every listing to a landed cost per milligram with freight included, then compare. Our source comparison handles the first step and this page handles the second.